Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anoge… (NCT05156541) | Clinical Trial Compass
CompletedPhase 3
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
Russia30 participantsStarted 2009-05-18
Plain-language summary
The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients of both sexes aged 18 to 50 years with a diagnosis of "Anogenital warts".
✓. The diagnosis "Anogenital warts" was made for the first time at least one year before inclusion in the study.
✓. During the last year prior to inclusion in the study, the patient had at least 2 recurrences of anogenital warts.
✓. The diagnosis is confirmed by the detection of HPV by polymerase chain reaction (PCR).
✓. Negative pregnancy test in women.
✓. Availability of written informed consent to participate in the study.
Exclusion criteria
✕. Positive test results for syphilis, hepatitis (HbsAg, anti-HCV), HIV infection, gonococcal infection, urogenital trichomoniasis, chlamydial infection, inflammatory diseases of the urogenital system caused by genital mycoplasmas.
✕. Unsystematic use of barrier methods of contraception.
✕. Pregnancy and lactation.
✕. Known allergic reactions to interferons and / or other significant allergic diseases.
✕. Any immunotropic therapy within the last 6 weeks prior to enrollment in the study.
✕. The need to take drugs prohibited during the study.
. Condition after organ transplantation, constant intake of immunosuppressive drugs.
✕. Severe pathology from the cardiovascular system (uncontrolled arterial hypertension, unstable angina pectoris, congestive heart failure, cardiac arrhythmias), a history of myocardial infarction or cerebrovascular accident within the last 6 months.